Fewer than one in 10 individuals that would benefit from obesity jabs such as Wegovy have access to them, caution the World Health Organization as it issues its inaugural advice on the medications.
Considering over a billion individuals worldwide currently living with obesity, it is advocating for increased and just availability to GLP-1 medication.
According to forecasts, over two billion will be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that obesity is a lifelong illness that can be managed with thorough and continuous care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are major obstacles to universal access to the jabs that can aid individuals in losing significant body mass, notes the body.
Skinny Jab Shortage
Even under the present most favorable case, the production of these medications might only reach around 100 million people – under 10% of the global need, per the health organization.
The recommendation encourages nations and manufacturers to widen availability, through strategies such as voluntary licensing.
The intellectual property rights on a key compound – the main component of a leading brand – is due to expire in a number of countries in 2026.
How Weight-Loss Jabs Operate
The injections replicate a body's own hormone to reduce digestion speed, reduce hunger and increase feelings of fullness so users eat less.
Individuals commonly see weight reduction within a few weeks of commencing the weekly injections.
Research points to patients may see weight return a year later of stopping the treatment, because their typical hunger resume.
Being overweight or obese elevates your risk for experiencing diseases, including type 2 diabetes, heart disease, stroke, and specific malignancies.
Obesity concerns individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, per the WHO.
